A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in
pediatric subjects (2 to <18 years old) with symptoms and clinical manifestations of Gaucher
disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase)
or PB-06-005 (naïve treatment with taliglucerase alfa).